Puretech Health Share Discussion Threads

[lendmeafiver] 10/9/2018 15:46

Yes, optimistic

[edwardt] 10/9/2018 15:12

everyone looking forward to tomorrow!!

[lendmeafiver] 04/9/2018 20:19

Thanks for that link, will certainly take a look.

[rambutan2] 04/9/2018 20:12

For anyone interested, it's 15.15 UK time:

resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced that company management will present a corporate overview at the Wells Fargo 2018 Healthcare Conference on Wednesday, September 5, 2018 at 10:15 a.m. ET in Boston, MA.

A live audio webcast of the presentation can be accessed on the Investors section of resTORbio’s website at . An archived replay will be available for at least 30 days following the presentation.

[lendmeafiver] 29/8/2018 09:34

Ok, two weeks

[lendmeafiver] 28/8/2018 21:07

Should be later this week, look forward to it.

[ascoyne] 28/8/2018 15:18

According to MarketScreener - interim results were due out today.

hxxps://www.marketscreener.com/PURETECH-HEALTH-PLC-22619613/calendar/

Don't see any sign of them so far?

[rambutan2] 28/8/2018 14:47

Last year the interims were released on the 30th, although no advance notice so far. I would expect them to be pretty upbeat about progress on a number of fronts.

[lendmeafiver] 28/8/2018 13:43

What is the next expected area of newsflow here? gelesis?

[countless] 19/8/2018 16:50

Tipped over the weekend

[rambutan2] 10/8/2018 03:02

And more good news from last week:

2 August 2018

PureTech Health plc

PureTech's Karuna Completes $42 Million Financing Round to Advance Lead Product Candidate for the Treatment of Disorders Marked by Psychosis and Cognitive Impairment

PureTech Health plc (LSE: PRTC) ("PureTech Health"), a clinical-stage biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG), today announced that its affiliate, Karuna, successfully completed a $42 million Series A financing round, including the issuance of $22 million in shares upon conversion of debt into equity. This financing round included ARCH Venture Partners, the Wellcome Trust, Steven Paul MD, PureTech Health, and other undisclosed investors.

Proceeds from the financing will be used to advance its lead product candidate, KarXT (Karuna-xanomeline-trospium chloride), including the initiation of a Phase 2 trial in patients with schizophrenia in the third quarter of 2018 and the expansion into other therapeutic areas, including a non-opiate pain indication.

Joep Muijrers, PhD, Chief Financial Officer at PureTech Health, said: "The financial commitment from these high-profile investors shows clear confidence in Karuna's approach to developing what could be the first new mechanism in over 50 years for the treatment of psychosis and cognitive impairment across central nervous system (CNS) disorders. As KarXT advances into a Phase 2 trial, we believe strongly in Karuna's unique mechanism of action and potential."

[rambutan2] 10/8/2018 03:00

Good news from yesterday:

PureTech's Akili Expands Series C Funding, Increasing Round to $68 Million, with $13 Million in New Investments

New Investors Include CLSA, Omidyar Technology Ventures, Digital Garage Group, and Fearless Ventures

PureTech Health plc (LSE: PRTC) ("PureTech Health"), a clinical-stage biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG), today announced that its independent affiliate, Akili, has raised $13 million in new funding as an extension of its recent Series C financing. The Series C extension brings the total equity financing Akili has raised this year to $68 million.

Participating investors include CLSA, Omidyar Technology Ventures, Digital Garage Group, and Fearless Ventures. Akili's initial Series C financing round was led by Temasek and included additional investors Baillie Gifford, Amgen Ventures, M Ventures (the CVC fund of Merck KGaA, Darmstadt, Germany), JAZZ Venture Partners, Canepa Advanced Healthcare Fund, and Brooklands Capital Strategies.

Akili will use the funds to further advance development and deployment of its pipeline of prescription digital treatment candidates, including its lead product candidate, AKL-T01, through key regulatory milestones and commercial preparations. Akili also plans to use the funds to advance a number of other digital treatments in development, including Major Depressive Disorder ("MDD"), multiple sclerosis ("MS") and various other inflammatory diseases.

Bharatt Chowrira, PhD, President and Chief of Business and Strategy at PureTech Health, said: "This financing is an additional validation for Akili and further augments their strong cash position as they progress on their path to offer potentially safe, effective, and personalised digital treatments for patients across a range of mental health and neurological conditions."

[edwardt] 26/7/2018 15:18

wow - if restorbio goes back to ten bucks i will buy some stateside. apparently lock in expires next week...

[edwardt] 25/7/2018 14:53

come off a chunk now stateside. interesting to see where it finishes!

[edwardt] 25/7/2018 13:49

i tried to buy prtc and was only offered 1000. the rise will come but it will lag.

[edwardt] 25/7/2018 13:48

you are spot on chap. i am pretty sure they have not sold any.

[elgordo] 25/7/2018 13:39

ResTORbio (NASDAQ: TORC) up 164% in pre-trading as of now. That's a marcap uplift of around $414m. PRTC own 34.9%, so adds $414x0.349/1.31 = approx £110m to the value of their holding. This equates to £110m/282.68m = 38.9p per share. Or have I got my maths wrong, as the market reaction certainly suggests?

(Pre-trading price dropping a little as I type, but still...)

[edwardt] 25/7/2018 13:10

restorbio going mental state side!

[danieldanj] 22/7/2018 21:35

Watch PureTech Health (PRTC) closely on potential $1B+ deal

[edwardt] 20/7/2018 13:15

Always has done but agree a promise of up to a billion in funding should get mr markets attention

[mirabeau] 20/7/2018 07:05

This looks interesting now

[edwardt] 16/7/2018 14:04

lets hope so. as much as i like help save the world, it would be nice to get rich along the way too.

[jthomas10] 12/7/2018 17:37

I agree, it feels like this is under the radar - which is fine by me as it helps accumulate a holding. However with cash balances of more than a third of the mcap and the sheer brilliance of the minds at work in this firm with the pipeline and partnerships, it won't be long before this will race past broker targets of £3.

[lendmeafiver] 12/7/2018 15:03

Very encouraging news, I purchased a few more here this week, well below ipo and share issue prices of course, I expect that at some stage this year there will be sufficient newsflow to really move the share price closer to the brokers targets of circa £3